Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

NCT04068103 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04068103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Lead sponsor
NRG Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 16, 2019
Completion date
June 21, 2026
Enrollment
635 (actual)
Sites
957

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, stage iia colon cancer ajcc v8